Astal Laboratories Ltd
Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs).[1]
- Market Cap ₹ 358 Cr.
- Current Price ₹ 81.7
- High / Low ₹ 103 / 60.4
- Stock P/E 24.3
- Book Value ₹ 79.1
- Dividend Yield 0.00 %
- ROCE 9.13 %
- ROE 7.96 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.03 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 4.53%
- Company has high debtors of 229 days.
- Promoter holding has decreased over last 3 years: -56.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 64 | 249 | |
| 51 | 228 | |
| Operating Profit | 13 | 21 |
| OPM % | 20% | 8% |
| 0 | 0 | |
| Interest | 1 | 2 |
| Depreciation | 0 | 1 |
| Profit before tax | 12 | 18 |
| Tax % | 25% | 17% |
| 9 | 15 | |
| EPS in Rs | 9.08 | 3.48 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 288% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 50% |
| 3 Years: | 43% |
| 1 Year: | -2% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 10 | 42 |
| Reserves | 26 | 292 |
| 13 | 50 | |
| 14 | 135 | |
| Total Liabilities | 63 | 518 |
| 11 | 268 | |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| 52 | 251 | |
| Total Assets | 63 | 518 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -13 | -18 | |
| -8 | -2 | |
| 3 | 3 | |
| Net Cash Flow | -17 | -17 |
| Free Cash Flow | -18 | -19 |
| CFO/OP | -96% | -80% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 157 | 229 |
| Inventory Days | 112 | 113 |
| Days Payable | 82 | 206 |
| Cash Conversion Cycle | 187 | 135 |
| Working Capital Days | 97 | 114 |
| ROCE % | 9% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Domestic share of revenue % ・Standalone data |
|
|
| Intermediates share of revenue % ・Standalone data |
||
| Third-party manufacturing active 0/1 (binary) ・Standalone data |
||
| Number of permanent employees count ・Standalone data |
||
| Own plant manufacturing active 0/1 (binary) ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Submission of Newspaper publication of financial results for the quarter ended 30th June, 2026.
-
Compliances- Statement Of Deviation & Variation
- Astal Laboratories filed Q1 FY27 deviation statement; no deviation in 306 lakh, 441 lakh and 33.99 lakh fund use.
-
Results- Financial Results For June 30, 2026
- Astal Laboratories approved Q1 FY27 results on 14 Aug 2026; standalone PAT Rs370.69 lakh, consolidated PAT Rs942.17 lakh.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, 14Th August, 2026
- Board approved Q1 FY2026 standalone and consolidated results; consolidated profit rose to Rs 942.17 lakh.
-
Board Meeting Intimation for Prior Intimation Of The Board Meeting To Be Held On 14Th August, 2026.
- Board meeting on 14 Aug 2026 to approve Q1 FY2026 standalone and consolidated results.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Update[1]
Astal Laboratories Limited (formerly Macro International Limited) was taken over in 2022 under SEBI takeover regulations, following which its objects were changed to manufacturing and sale of pharmaceutical intermediates and bulk drugs. The name was subsequently changed to Astal Laboratories Limited in May 2024.